


Supplemental Figure 1: Stable expression of NKG2C on NK cells from the blood of CMV⁻ and EBV⁻ individuals

PBMC from healthy controls (CMV⁻ and EBV⁻seronegative, n=3) at four timepoints between 2007 and 2010 were analyzed by flow cytometry for NKG2C and CD57 expression. Frequency per individual of CD3⁺CD56^{bright}CD16⁻ NK cells that are NKG2C^{dim}CD57⁻ (left panel) and of CD3⁺CD56^{dim}CD16⁺ NK cells that are NKG2C^{hi}CD57⁺ (right panel).



Supplemental Figure 2: Stable KIR expression on CD56^{dim} NK cells from the blood of CMV⁻ and EBV⁻ individuals

PBMC from healthy controls (CMV⁻ and EBV⁻ seronegative, n=3) at four timepoints between 2007 and 2010 were analyzed by flow cytometry for expression of the KIRs - 2DL2/3/DS2, -3DL1, -3DL2, and -2DL1/DS1 by CD3⁻CD56^{dim}CD16⁺ NK cells. Graphs show percentage of KIR⁺ cells for each individual at various timepoints.